{
  "docId": "019de074-5234-763a-a0be-96f5f1aa05d9",
  "docSlug": "9279d19020d2e95032dc34a127aaa2e7",
  "documentTitle": "Compass Therapeutics | Investor Presentation Deck | 40 slides",
  "authorId": "compass-therapeutics",
  "authorName": "Compass Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 40,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 8,
  "notes": "The slide uses a side-by-side comparison to highlight the superior ORR, PFS, and OS of CTX-009 compared to historical benchmarks like FOLFOX and TOPAZ-1.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-5234-763a-a0be-96f5f1aa05d9/23",
  "deckHref": "/decks/019de074-5234-763a-a0be-96f5f1aa05d9",
  "deckJsonHref": "/decks/019de074-5234-763a-a0be-96f5f1aa05d9.json",
  "deckAnchorHref": "/decks/019de074-5234-763a-a0be-96f5f1aa05d9#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.54,
        "y": 0.33
      },
      "kind": "list",
      "text": "FOLFOX (NCCN guidelines): 5% ORR in the second-line setting, 4.0 month median PFS, 6.2 month median OS. TOPAZ-1 (Phase 3 study): 26.7% ORR for Gem/Cis/Durvalumab (anti PD-L1) in the first-line setting",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0ecaa0bf-b957-4306-ac59-8866fd94b53a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.06,
        "y": 0.33
      },
      "kind": "list",
      "text": "24 patients with BTC have been enrolled and dosed. 10 partial responses (PRs) for a 37.5% ORR in patients treated in the second- and third-line settings (64% ORR of patients treated in the 2nd line setting). Median PFS 9.4 months. Median OS 12.5 months.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6f351335-018d-4413-bd73-bbede97f94a7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.6,
        "x": 0.04,
        "y": 0.16
      },
      "kind": "title",
      "text": "CTX-009 Interim Phase 2 Study Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6893c4f3-1dca-4816-94ba-37406459ef7b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "85b850f9-8ba6-4117-9a6c-3e096f277357",
      "evidence": "24 patients with BTC have been enrolled and dosed.",
      "confidence": 0.7
    },
    {
      "name": "Data Story Arc",
      "slug": "data-story-arc",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "3bdb8f22-219b-45d3-8565-0475d06ed21c",
      "evidence": "10 partial responses (PRs) for a 37.5% ORR in patients treated in the second- and third-line settings",
      "confidence": 0.6
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "d4d632e9-b1d5-4d20-996d-e3d402164d4e",
      "evidence": "Side-by-side presentation of internal data vs external benchmarks",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 40,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "f0a32b3c-a238-480c-9a9d-c05166154467",
      "evidence": "The document implies that the current state of cancer treatment is inadequate and that innovative therapies are needed.",
      "position": 0,
      "objective": "The cost of inaction in cancer treatment",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 40,
      "from": 7,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "6979bcd9-f71b-4757-b297-1c4753563587",
      "evidence": "The document presents data and results for each of these therapies.",
      "position": 1,
      "objective": "The potential benefits of CTX-009, CTX-471, and CTX-8371",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 0.6,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}